About Xstrahl
Xstrahl is a Healthcare company based in Camberley (United Kingdom) founded in 2000, and was acquired by Risk Capital Partners in March 2018. Superficial and orthovoltage medical X-Ray system for cancer. The company has 17 employees. Its chief executive, as recorded, is Adrian Treverton. Xstrahl offers products and services including Xstrahl 100, Xstrahl 150, Xstrahl 200, Xstrahl 300, and SARRP. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its legal entity is XSTRAHL LIMITED.
Company details
Xstrahl, formerly known as Gulmay Medical is developing X-ray therapy systems for cancer and dermatology treatment along with radiation biology research. The company has developed a customisable radiation biology research system, known as Small Animal Radiation Research Platform (SARRP). Xstrahl 100 and 150 X-ray therapy systems have a low energy option for superficial treatment of clinical indications like basal cell carcinoma, squamous cell carcinoma, keloid scars, dermatological conditions and mycosis fungoides. Xstrahl 200 and 300 X-ray therapy systems are similar to the previous systems along with orthovoltage capability which helps in providing palliative treatment and treatment of benign conditions like inflammatory disorders, degenerative disorders and hypertrophic disorders.
- Headquarters Camberley, United Kingdom
- Employees 17
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website xstrahl.com
- Social LinkedIn X Facebook Instagram
- Acquired by Risk Capital Partners (Mar 2018)
- Legal Name Xstrahl Limited
- Date of Incorporation 22 Sep, 1995
- Jurisdiction WALSALL, WEST MIDLANDS, UNITED KINGDOM
- Annual Revenue$9.57 M (USD)21as on Dec 31, 2020
- Net Profit-$33.37 K (USD)-118as on Dec 31, 2020
- Investors
- Employee Count17
- Acquired byRisk Capital Partners
(Mar 2018)
Products & Services of Xstrahl
Xstrahl offers a comprehensive portfolio of products and services, including Xstrahl 100, Xstrahl 150, Xstrahl 200, Xstrahl 300, and SARRP.
Radiation device for treating skin cancer and keloids
System for skin cancer and benign condition therapy
Orthovoltage radiotherapy for superficial lesions
Advanced radiation therapy for medical applications
Image-guided irradiator for preclinical research
Investors in Xstrahl
Xstrahl has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Risk Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are made to support ambitious entrepreneurs. | 2001 | riskcapitalpartners.co.uk | London, United Kingdom |
Investor details for Xstrahl
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Xstrahl
1 people are tracked at Xstrahl (1 in leadership); the tracked headcount is 17.
| Name | Role | Group |
|---|---|---|
Adrian Treverton | CEO | Leadership |
Complete people profiles for Xstrahl
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Xstrahl
2 dated milestones of Xstrahl across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Xstrahl is founded.
- Exit Acquired by Risk Capital Partners.
Web traffic of Xstrahl
The website of Xstrahl (xstrahl.com) receives about 4.8K visits a month.
- Monthly visits4.8K
▼ 8.8% vs previous month
Websites whose visitors overlap most with Xstrahl. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
aesthetic-solutions.com | aesthetic-solutions.com | 100% | #1,908,954 | – | |
medicalexpo.com | medicalexpo.com | 95% | #86,193 | – | |
| forteresearch.com | 62% | View details | |||
| vhio.net | 62% | 86.9K | #388,215 | View details | |
| inoncology.com | 62% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Xstrahl
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xstrahl
Complete news archive for Xstrahl
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xstrahl
Xstrahl was founded in 2000.
Xstrahl is headquartered in Camberley, United Kingdom. It is registered at Camberley, Surrey, United Kingdom.
Adrian Treverton is the CEO of Xstrahl, as recorded in our data.
Xstrahl has 17 employees.
Annual revenue of Xstrahl is $9.57M as on Dec 31, 2020.
Xstrahl, formerly known as Gulmay Medical is developing X-ray therapy systems for cancer and dermatology treatment along with radiation biology research. The company has developed a customisable radiation biology research system, known as Small Animal Radiation Research Platform (SARRP). Xstrahl 100 and 150 X-ray therapy systems have a low energy option for superficial treatment of clinical indications like basal cell carcinoma, squamous cell carcinoma, keloid scars, dermatological conditions and mycosis fungoides. Xstrahl 200 and 300 X-ray therapy systems are similar to the previous systems along with orthovoltage capability which helps in providing palliative treatment and treatment of benign conditions like inflammatory disorders, degenerative disorders and hypertrophic disorders.
Xstrahl offers Xstrahl 100, Xstrahl 150, Xstrahl 200, Xstrahl 300, and SARRP.
Xstrahl has 1 investor. Key investors include Risk Capital Partners.
Xstrahl operates through Xstrahl Limited.
Yes. Xstrahl was acquired by Risk Capital Partners in March 2018.